Extended Data Fig. 7: Early type I IFN signalling promotes germinal centre B cells and antiviral antibody responses.
a, Quantification of IgD- CD95+ germinal centre (GC) B cells (left)—expressed as percentage of B220+ cells—and of IgG1+ cells (right)—expressed as percentage of B220+ B cells—in the dLNs of mice treated with anti-IFNAR blocking antibody (or isotype control), and infected with rVSV 14 days earlier. Mean + /- SEM is shown. n = 3. An unpaired two-tailed t test was applied. *** p value < 0.001. b, GP–binding IgG1 Abs (expressed as fold induction over uninfected controls) were measured in the sera of mice described in panel A, 14 days after rVSV infection. Data are pooled from 2 independent experiments. Mean ± SEM is shown. n = 7. An unpaired two-tailed t test was applied. * p value < 0.05. c, Schematic representation of experimental procedure for the results described in Fig. 3d–f. 1 × 106 purified CD45.1+ Ag-specific (SMARTA) CD4+ T cells were transferred to CD45.2+ WT recipients and treated anti-IFNAR1 blocking antibody either 1 day prior to (light blue) or 1 day after (yellow) rVSV infection.
